Local ethic review board (Fujian Cancer Hospital) approved the study (No. K2024-286-01), and patient informed consent was deemed unnecessary, given its retrospective nature. Fig 1. Study profile for ...

Abbreviations: BS, brainstem injury; CN, cranial nerve injury; NR, not reported; OP, optice nerve or chiasm injury; OS, overall survival; TLN, temporal lobe necrosis. Randomized study; percentage is ...

李振彰博士团队的研究方法使用了深度学习算法，通过训练模型，使其能够从海量内窥镜图像中学习并识别出可能的癌症病变。这一过程不仅提升了早期诊断的准确性，也大大降低了对专业医疗设备的依赖，为基层医疗提供了更加便捷和可及的解决方案。

Tevimbra is under clinical development by BeiGene and currently in Phase III for Nasopharyngeal Cancer. According to GlobalData, Phase III drugs for Nasopharyngeal Cancer have a 67% phase transition ...

Linavonkibart is under clinical development by Scholar Rock and currently in Phase I for Nasopharyngeal Cancer.

(RDY) said that it has launched Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma. Toripalimab is a New Biological Entity (NBE).

Cash-strapped Viracta Therapeutics is continuing to reduce its options in order to stay afloat. Less than two months after ...

Nasopharyngeal carcinoma (NPC) is a rare, aggressive form of head and neck cancer that originates in the nasopharynx, the upper part of the throat. The company has launched Toripalimab, a new ...

in India under the brand name Zytorvi for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC), a rare form of head and neck cancer. Loqtorzi, a novel anti-PD-1 ...